BR0013043A - Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante - Google Patents
Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinanteInfo
- Publication number
- BR0013043A BR0013043A BR0013043-5A BR0013043A BR0013043A BR 0013043 A BR0013043 A BR 0013043A BR 0013043 A BR0013043 A BR 0013043A BR 0013043 A BR0013043 A BR 0013043A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- acid molecule
- isolated
- animals
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/852—Sperm
- Y10S530/853—Ovary; eggs; embryos
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"PROTEìNA ISOLADA, ANTICORPO ISOLADO, COMPOSIçãO, MéTODO DE REGULAçãO DE REAçãO IMUNOLóGICA EM ANIMAIS, MéTODO DE TRATAMENTO DE CâNCER EM ANIMAIS, MOLéCULA DE áCIDO NUCLEICO ISOLADO, MOLéCULA DE áCIDO NUCLEICO RECOMBINANTE, CéLULA RECOMBINANTE E VìRUS RECOMBINANTE". é descrita uma proteína de Fator de Ativação de Citoquinas (CAF), uma molécula de ácido nucleico isolado que codifica uma proteína de CAF, um anticorpo que se une seletivamente a uma proteína de CAF, uma composição que compreende um Fator de Ativação de Citoquinas (CAF) e um método de modulação do sistema imunológico utilizando a composição. Também é descrito um método de tratamento de câncer que utiliza essa composição.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14531799P | 1999-07-23 | 1999-07-23 | |
| US19761900P | 2000-04-14 | 2000-04-14 | |
| PCT/US2000/019643 WO2001007472A1 (en) | 1999-07-23 | 2000-07-19 | Highly purified cytokine activating factor and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0013043A true BR0013043A (pt) | 2002-04-30 |
Family
ID=26842849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0013043-5A BR0013043A (pt) | 1999-07-23 | 2000-07-19 | Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6420337B1 (pt) |
| EP (1) | EP1198475B1 (pt) |
| JP (1) | JP4763193B2 (pt) |
| CN (1) | CN1376163A (pt) |
| AR (1) | AR033340A1 (pt) |
| AT (1) | ATE290017T1 (pt) |
| AU (1) | AU778239B2 (pt) |
| BR (1) | BR0013043A (pt) |
| CA (1) | CA2379251A1 (pt) |
| CO (1) | CO5290297A1 (pt) |
| DE (1) | DE60018426T2 (pt) |
| ES (1) | ES2239019T3 (pt) |
| IL (1) | IL147716A0 (pt) |
| MX (1) | MXPA02000779A (pt) |
| MY (1) | MY125980A (pt) |
| NZ (1) | NZ516744A (pt) |
| TW (1) | TWI250164B (pt) |
| WO (1) | WO2001007472A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040105710A (ko) * | 2002-02-11 | 2004-12-16 | 아르키온 라이프 사이언씨즈 엘엘씨 | 정제된 사이토킨 억제인자 |
| US20040005327A1 (en) * | 2002-05-16 | 2004-01-08 | Subramanian Iyer | Immune T-cell stimulation |
| WO2006069779A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Preparing of peptides with excellent solubility |
| US20080071067A1 (en) * | 2006-09-20 | 2008-03-20 | Avigenics, Inc. | Methods of purifying proteins from egg white |
| US7852810B1 (en) * | 2007-01-03 | 2010-12-14 | Sprint Spectrum L.P. | Dynamic adjustment of forward-link frame-error-rate (FFER) target |
| US7813323B1 (en) | 2007-06-13 | 2010-10-12 | Sprint Spectrum L.P. | Dynamic adjustment of reverse-link frame-error-rate (RFER) target based on reverse-link RF conditions |
| US8107988B1 (en) | 2008-07-25 | 2012-01-31 | Sprint Spectrum L.P. | Conducting power control based on reverse-link RF conditions |
| AU2009289479B2 (en) * | 2008-09-05 | 2014-10-30 | Cardiopolymers, Inc. | Process for generating microwalled encapsulation balloons |
| US8477686B1 (en) | 2009-09-10 | 2013-07-02 | Sprint Spectrum L.P. | Automatic increase of target frame error rate for duration based on call drop timer |
| US8290532B1 (en) | 2010-04-19 | 2012-10-16 | Sprint Spectrum L.P. | Selectively conducting reverse-link power control and call admission control |
| US8537700B1 (en) | 2010-04-19 | 2013-09-17 | Sprint Spectrum L.P. | Identifying and selectively controlling reverse-noise contribution on a per-access-terminal basis |
| CN104288769B (zh) * | 2014-09-17 | 2017-09-29 | 陕西建华生物制药有限公司 | 一种西药外用膏剂及其制备方法 |
| JP5894695B1 (ja) * | 2015-05-25 | 2016-03-30 | ホーユー株式会社 | ウズラの卵アレルギーの抗原 |
| US10632158B2 (en) | 2016-06-23 | 2020-04-28 | IgY Nutrition | Use of a hyperimmune egg product to prevent and treat dysbiosis |
| US10450364B2 (en) | 2017-02-13 | 2019-10-22 | Arkion Life Sciences, Llc | Hyperimmunized egg product for treatment of necrotic enteritis in poultry |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119279D0 (en) * | 1991-09-10 | 1991-10-23 | Ici Plc | Modification of lignin synthesis in plants |
| WO1998028419A2 (en) * | 1996-12-20 | 1998-07-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulation of vesicular release |
-
2000
- 2000-07-19 BR BR0013043-5A patent/BR0013043A/pt not_active IP Right Cessation
- 2000-07-19 NZ NZ516744A patent/NZ516744A/en unknown
- 2000-07-19 CA CA002379251A patent/CA2379251A1/en not_active Abandoned
- 2000-07-19 ES ES00947517T patent/ES2239019T3/es not_active Expired - Lifetime
- 2000-07-19 DE DE60018426T patent/DE60018426T2/de not_active Expired - Lifetime
- 2000-07-19 AU AU61106/00A patent/AU778239B2/en not_active Ceased
- 2000-07-19 MX MXPA02000779A patent/MXPA02000779A/es active IP Right Grant
- 2000-07-19 CN CN00813327A patent/CN1376163A/zh active Pending
- 2000-07-19 JP JP2001512555A patent/JP4763193B2/ja not_active Expired - Fee Related
- 2000-07-19 WO PCT/US2000/019643 patent/WO2001007472A1/en active IP Right Grant
- 2000-07-19 IL IL14771600A patent/IL147716A0/xx unknown
- 2000-07-19 EP EP00947517A patent/EP1198475B1/en not_active Expired - Lifetime
- 2000-07-19 AT AT00947517T patent/ATE290017T1/de not_active IP Right Cessation
- 2000-07-20 US US09/620,093 patent/US6420337B1/en not_active Expired - Lifetime
- 2000-07-21 TW TW089114621A patent/TWI250164B/zh not_active IP Right Cessation
- 2000-07-21 MY MYPI20003352A patent/MY125980A/en unknown
- 2000-07-21 AR ARP000103782A patent/AR033340A1/es not_active Application Discontinuation
- 2000-07-24 CO CO00055349A patent/CO5290297A1/es not_active Application Discontinuation
-
2002
- 2002-05-14 US US10/146,657 patent/US20030143190A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR033340A1 (es) | 2003-12-17 |
| TWI250164B (en) | 2006-03-01 |
| NZ516744A (en) | 2004-01-30 |
| EP1198475A4 (en) | 2003-05-14 |
| US6420337B1 (en) | 2002-07-16 |
| JP4763193B2 (ja) | 2011-08-31 |
| AU778239B2 (en) | 2004-11-25 |
| MY125980A (en) | 2006-09-29 |
| DE60018426D1 (de) | 2005-04-07 |
| ATE290017T1 (de) | 2005-03-15 |
| CN1376163A (zh) | 2002-10-23 |
| EP1198475A1 (en) | 2002-04-24 |
| WO2001007472A1 (en) | 2001-02-01 |
| US20030143190A1 (en) | 2003-07-31 |
| DE60018426T2 (de) | 2006-05-11 |
| JP2003506019A (ja) | 2003-02-18 |
| AU6110600A (en) | 2001-02-13 |
| ES2239019T3 (es) | 2005-09-16 |
| IL147716A0 (en) | 2002-08-14 |
| EP1198475B1 (en) | 2005-03-02 |
| CA2379251A1 (en) | 2001-02-01 |
| MXPA02000779A (es) | 2003-10-15 |
| CO5290297A1 (es) | 2003-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0013043A (pt) | Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante | |
| EE05496B1 (et) | Antikeha, mis seob osteoprotegeriini siduvat valku | |
| NO961115D0 (no) | Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser | |
| TR199900666T2 (xx) | �nsan paratormonu ile ilgili peptidlere kar�� antikor. | |
| DK0554344T3 (da) | Farmaceutisk præparat til behandling eller forebyggelse af en malign tumor | |
| BG60256B1 (bg) | Рекомбинантен метод за получаване на лимфотоксин | |
| DE69734882D1 (de) | Dna immunisierung gegen chlamydia infektion | |
| UA102988C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕН-СВЯЗЫВАЮЩАЯ ЧАСТЬ, КОТОРАЯ СВЯЗЫВАЕТ TNFα ЧЕЛОВЕКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, В КОТОРОМ АКТИВНОСТЬ TNFα ЯВЛЯЕТСЯ ВРЕДНОЙ | |
| HUP0004639A2 (hu) | Chlamydia fehérje, génszekvencia és ezek alkalmazása | |
| MXPA02008239A (es) | Gen humano de la esquizofrenia. | |
| BR9904475A (pt) | Molécula tipo anticorpo anti-fas, humanizada, agente para a profilaxia e/ou tratamento de condições envolvendo uma anormalidade no sistema ligando fas/fas, uso de um anticorpo, dna, vetor de dna recombinante, célula hospedeira, processo para produzir um anticorpo anti-pas, cepa transformante de e.coli, e, polipeptìdeo. | |
| DE69535855D1 (de) | Calciumbindende rekombinante antikörper gegen protein c | |
| BR9710975A (pt) | Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis | |
| DE3751319D1 (de) | VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN. | |
| DE69839582D1 (de) | Neues polypeptid, dafür kodierende dna und deren verwendungen | |
| BR9803296A (pt) | Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma. | |
| ES2164169T3 (es) | Proteinas estimulantes de celulas t de pestivirus. | |
| ITRM920506A1 (it) | Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi. | |
| RU2004106773A (ru) | Антитело против интерферон-альфа/бета-связывающего белка ii (ifnab-bpii) | |
| BR0207253A (pt) | Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado | |
| ATE435915T1 (de) | Spezifische nukleinsäuren und polypeptide aus krankheitserregenden stämmen von neisseria | |
| EE04819B1 (et) | Rekombinantne DNA molekul ja ekspressioonivektorit sisaldav peremeesrakk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B15V | Prolongation of time limit allowed |
Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 18 (DEZOITO) DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |